HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

F. Sclafani, A. Roy, D. Cunningham, A. Wotherspoon, C. Peckitt, D. Gonzalez De Castro, J. Tabernero, B. Glimelius, A. Cervantes, Z. Eltahir, J. Oates, I. Chau

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Fingerprint Dive into the research topics of 'HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab'. Together they form a unique fingerprint.

Medicine & Life Sciences